Detalhe da pesquisa
1.
An open randomized multicentre Phase 2 trial to assess the safety of DAV132 and its efficacy to protect gut microbiota diversity in hospitalized patients treated with fluoroquinolones.
J Antimicrob Chemother
; 77(4): 1155-1165, 2022 03 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-35016205
2.
Protection of the Human Gut Microbiome From Antibiotics.
J Infect Dis
; 217(4): 628-636, 2018 01 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-29186529
3.
Adherence to treatment and quality of life during hepatitis C therapy: a prospective, real-life, observational study.
Liver Int
; 31(4): 516-24, 2011 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21382162
4.
A Colon-Targeted Adsorbent (DAV132) Does Not Affect the Pharmacokinetics of Warfarin or Clonazepam in Healthy Subjects.
Clin Pharmacol Drug Dev
; 10(8): 908-917, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33434399
5.
Patient education improves adherence to peg-interferon and ribavirin in chronic genotype 2 or 3 hepatitis C virus infection: a prospective, real-life, observational study.
World J Gastroenterol
; 14(40): 6195-203, 2008 Oct 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-18985810
6.
Maintenance therapy and 3-year outcome of opioid-dependent prisoners: a prospective study in France (2003-06).
Addiction
; 104(7): 1233-40, 2009 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-19426291
7.
Hepatitis B virus genotypes and extrahepatic manifestations.
J Hepatol
; 43(5): 764-70, 2005 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-16087273